No­vavax says its vac­cine is 80% ef­fec­tive in teens, but man­u­fac­tur­ing ques­tions con­tin­ue to cloud fu­ture

No­vavax fi­nal­ly sub­mit­ted an ap­pli­ca­tion for emer­gency use au­tho­riza­tion for its Covid-19 vac­cine late last month. Now a sec­ond ap­pli­ca­tion may al­ready be in the off­ing.

The oft-de­layed but nev­er-bor­ing Mary­land-based vac­cine com­pa­ny an­nounced pos­i­tive re­sults from its ado­les­cent tri­al on Thurs­day. The biotech’s vac­cine, known as Nu­vax­ovid, was 80% ef­fec­tive at pre­vent­ing symp­to­matic dis­ease in pa­tients 12 to 17 years old.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN